There is no cure for Alzheimer's today. Two approved antibodies, lecanemab and donanemab, slow early-stage decline by roughly a quarter to a third. That's real but modest, and they carry a risk of brain swelling and bleeding. Our view: the cure will look like prevention. Blood tests will flag the disease years before symptoms, and faster, safer drugs will clear it early.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Treatment decisions belong with a neurologist or memory-clinic specialist.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your neurologist or memory-clinic specialist.
Could tau drugs work best in a short window, when blood tau-tangle markers first rise? If so, a validated blood test that does not yet exist could show when to add a tau drug to amyloid removal, and the pair might slow the disease more than either alone. Trials could test whether people with lower blood tau-tangle levels gain more from the added drug.
What would prove it wrong: if people given a tau drug as blood tau-tangle markers first rise do no better than those treated later, or than amyloid removal alone.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
Researchers analyzed DNA from over 109,000 people with Alzheimer's and about 2.1 million controls and found 118 common gene regions tied to risk, 48 of them new. Genes more active in microglia (brain immune cells) and less active in neurons were enriched for risk. This points to new drug targets but is not a treatment.
In 619 people with early Alzheimer's, 72 weeks of the combination did not beat either drug alone on the main memory-and-daily-function score (CDR-SB; p = 0.675 vs cromolyn, p = 0.276 vs ibuprofen). People without the APOE4 gene did somewhat better on the combination than on placebo, but that was not statistically significant. The authors say it was well tolerated and that this hint needs a new trial. Authors are linked to the developer.
In 41 people randomized to sham, a very low dose or a low dose of whole-brain radiation, the 6-month memory-test goal (ADAS-cog) was not met. Some 12-month exploratory results looked better at the higher dose (nominal p = 0.044), but the authors say they did not prove it works and a larger trial is needed. No treatment-related side effects were reported.
Actinogen says the trial database was locked on October 20, so the data are final and no results have been released. Topline results, previously guided to "November", are now expected in mid-November. The trial compares Xanamem 10 mg with placebo over 36 weeks in 247 people. Company announcement, not peer-reviewed.
In a Phase 1 trial of 115 people, an oral pill that switches on TREM2, a receptor on the brain's immune cells, was well tolerated at doses up to 140 mg a day and lowered a spinal-fluid marker showing it reaches its target. It was not tested for memory or thinking, so it is not yet shown to help. Sanofi is developing it as SAR448851.
NewAmsterdam Pharma started dosing in a randomized, placebo-controlled trial of its cholesterol-lowering pill in about 400 people aged 55 to 85 with early Alzheimer's signs in the blood but no symptoms. The main measure is change in blood p-tau217 after one year. No results yet, and the idea rests on small or indirect earlier data.
In mice and about 1,200 people, higher levels of imidazole propionate, made by gut bacteria, went with more amyloid and tau buildup and faster mental decline. It shows a link, not proof of cause, and no treatment follows from it yet.
A large health-record study linked the joint supplement glucosamine to a 25% higher chance of mild cognitive impairment progressing to dementia. Observational only.
Final patient visit completed in 247 participants. Topline results expected in November 2026.
Lilly's O-GlcNAcase inhibitor did not slow early symptomatic Alzheimer's.
Once-daily pill eased psychosis symptoms in Alzheimer's with placebo-like safety. Moving to pivotal trials.
In APOE4 carriers with mild cognitive impairment, the oral drug lowered blood p-tau217, and biomarker drops tracked with clinical and MRI benefits. A secondary analysis, not a new approval-grade result.
PrecivityAD2 and Elecsys pTau217 bring the total to four FDA-cleared Alzheimer's blood tests. PrecivityAD2 covers symptomatic adults 40 and up.
92% below the amyloid threshold at 28 weeks on the high dose. Eight microbleeds and one case of brain swelling in the maintenance period.
Trontinemab in 1,600 people with no symptoms but high blood p-tau217, measuring time to clinical decline.
People with very high blood p-tau217 had an estimated 78% risk of cognitive impairment within 10 years. Blood tests also helped primary-care doctors diagnose almost as accurately as specialists.
An early randomized trial testing whether boosting the immune system can help the brain clear Alzheimer's damage. Safety-stage results.
Canada's second Alzheimer's drug that targets the disease itself, after lecanemab in October 2025.
Lithium chloride reduced harmful tau changes and affected other Alzheimer's pathways in lab models.
Published in The Lancet: no slowing of early Alzheimer's over two years in nearly 3,800 people.
FDA accepted Leqembi Iqlik under-the-skin injection for review as a starting dose, under priority review.
Europe's medicines committee found the evidence didn't show the oral drug works. The company sought a re-examination.
For the first time, approved drugs slow early Alzheimer's instead of only easing symptoms. The benefit is modest, and they only work for people diagnosed early, which is why the new blood tests matter.
Clears amyloid and slowed decline by about 27% over 18 months in the CLARITY AD trial. It now comes as an at-home under-the-skin injection for maintenance, and the FDA is reviewing that injection as a starting dose.
Treatment can stop once amyloid is cleared. In TRAILBLAZER-ALZ 2 it slowed decline by about 35% in people with lower tau levels. A modified dosing schedule cut brain-swelling side effects.
Designed to cross into the brain more easily. At the high dose, 92% of patients fell below the amyloid threshold by 28 weeks, with relatively low side-effect rates. Phase 3 and the PrevenTRON prevention trial are under way.
Blood tests for p-tau217 and related markers now help diagnose Alzheimer's without a PET scan or spinal tap. One is cleared for adults as young as 40 with symptoms.
An oral pill that lowers excess cortisol in the brain, tested in mild-to-moderate Alzheimer's with high pTau181. The last patient visit was September 22, 2026.
In nearly 3,800 people over two years, oral semaglutide (the Ozempic/Wegovy drug) didn't slow early Alzheimer's, despite small changes in spinal-fluid markers.
| Treatment | For | What it does |
|---|---|---|
| Donepezil, rivastigmine, galantamine | Mild to severe | Boost the memory chemical acetylcholine. Ease symptoms for a time, but don't slow the disease. |
| Memantine | Moderate to severe | Calms overactive glutamate signals. Modest symptom benefit. |
| Lecanemab (2023), donanemab (2024) | Early disease with confirmed amyloid | Clear amyloid and slow decline. Need MRI monitoring for swelling or bleeding (ARIA). |
| Brexpiprazole | Agitation in dementia | The first drug approved specifically for Alzheimer's agitation. |
No supplement prevents or cures Alzheimer's. Lifestyle has stronger evidence than any pill on a store shelf. We rate each by the strength of human evidence.
U.S. POINTER (JAMA, 2025): regular exercise, the MIND diet, mental and social challenge, and health checks protected thinking skills over two years compared with a self-guided program.
Among the 14 risk factors the 2024 Lancet Commission links to about 45% of dementia cases. Hearing aids, blood-pressure control and cholesterol care are low-risk steps.
Leafy greens, berries, nuts, olive oil and fish are linked to slower cognitive aging, and the diet is part of the POINTER program.
Promising lab results, including 2026 data on tau. There's no human proof yet. Lithium can harm the kidneys and thyroid, so don't take it on your own.
Controlled trials in people who already have Alzheimer's didn't slow decline. Fish in the diet is still reasonable.
A large prevention trial in older adults found it didn't reduce dementia.
A September 2026 health-record study linked it to faster progression from mild impairment to dementia. Ask your doctor if you take it.
Be careful: "memory" supplements are sold with big claims and little evidence. Some common medicines, such as strong anticholinergic sleep and allergy pills, can worsen confusion in older adults. Review every pill and supplement with the care team.
Centers recognized for expertise in this condition, and communities of people living with it.
Funded by the National Institute on Aging as one of its Alzheimer's Disease Research Centers.
Designated and funded by the National Institute on Aging as one of the nation's Alzheimer's Disease Research Centers.
A research center funded by the National Institute on Aging through a federal P30 grant.
Funded by the National Institute on Aging as a formal Alzheimer's research and diagnosis program.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
You don't have to face Alzheimer's alone. These groups connect patients, families and caregivers with people who understand. Most are free.
The Alzheimer's Association's free online community, with message boards, private groups and Spanish discussions.
Join ↗Free local groups by phone, video or in person, led by trained facilitators.
Find a group ↗Alzheimer's Society's busy online forum, open around the clock.
Visit forum ↗Resources and support for people caring for a loved one with dementia.
Learn more ↗An open Reddit community about Alzheimer's disease.
Open on Reddit ↗A larger Reddit community for everyone dealing with any type of dementia.
Open on Reddit ↗A Reddit community specifically for people caring for loved ones.
Open on Reddit ↗Many caregiver groups. This link searches Facebook (a login is required).
Search Facebook ↗Most Alzheimer's communities focus on caregivers. The Alzheimer's Association's 24/7 Helpline is 800-272-3900.
Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Think about your privacy, because Reddit and many forums are public, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Most wealthy countries have now approved the amyloid drugs, but on different terms. Japan and China moved fast, Europe limited who can get donanemab, and the UK approved both but won't fund them on the NHS.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Cholinesterase drugs, memantineSymptom treatment | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Lecanemab (Leqembi)Early Alzheimer's | 2023 | 2025 | 2024, not on NHS | 2025 | 2023 | 2024 | 2024 | 2025 | — |
| Donanemab (Kisunla)Early Alzheimer's | 2024 | 2025, limited | Yes, not on NHS | 2026 | 2024 | — | Yes | 2025 | — |
| BlarcamesineOral, early Alzheimer's | — | Rejected 2025 | — | — | — | — | — | — | — |
| p-tau blood testsDiagnosis | 2025 | — | — | — | — | — | — | — | — |
Japan approved lecanemab within months of the U.S. and covers it under national insurance. A survey of 311 specialists after the first year points to infrastructure, not approval, as the main bottleneck.
The UK regulator approved both drugs, but NICE recommended against routine NHS use on cost grounds. Patients mostly can only get them privately. Approved isn't the same as available.
The EU approved donanemab only after a re-examination, and only for people who don't carry two copies of APOE4, the group at highest risk of brain swelling.
Alzheimer's starts quietly, many years before memory loss, when a sticky protein called amyloid builds up between brain cells. Amyloid then sets off tangles of another protein, tau, inside the cells. As the tau spreads, brain cells die.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations exist to help families affected by Alzheimer's pay for care and costs, mostly respite care so caregivers can take a break. Funds are limited and rules vary, so contact each one directly.
Care grants pay for 100 hours of in-home care or 24 days at an adult day center, used within 3 months. Applications are reviewed monthly, a decision can take 60 to 90 days, and awards have no cash value.
See the program ↗Up to $500, no more than once a year, to hire a home health agency or private caregiver for a short break. Funds come from private donors, are limited and go to those in greatest need.
See the program ↗Pays caregivers back for a sitter, home health aide or adult day program, up to $1,200 in 12 months. You must enroll and be pre-approved, and there may be a wait depending on funding.
See the program ↗Run by the Parker Jewish Institute. Pays for up to $1,800 a year of respite care at home, at an adult day center or as an occasional overnight stay. Funding is limited and may run out.
See the program ↗Pays for short-term respite care from a partner home-care agency. Scholarships are awarded monthly, with applications due the last day of each month. The page gives no amounts.
See the program ↗Donor-funded respite scholarships help pay for adult day programs, in-home care or overnight care in some parts of Michigan. Call the 24/7 Helpline (800-272-3900) to check eligibility.
See the program ↗Its donor-funded Family Assistance Program Grant pays for urgent needs, home-care supplies, minor home changes, utility bills and counseling. It was marked closed when checked; grants stay open only until funds run out.
Check status ↗Helps pay prescription copays or Medicare Part B premiums for treating psychosis in people with Alzheimer's or another dementia. It is not a general Alzheimer's fund. Listed as open on October 6, 2026; funds can run out.
Check fund status ↗Helps pay copays, deductibles and insurance premiums. The fund was listed as closed on October 6, 2026; the page offers alerts for when it reopens.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 2, 2026.
The omega-3, ginkgo, MIND-diet and anticholinergic-medicine notes, the 15–20-year amyloid timeline, the under-1% inherited figure, and the 27% / 35% trial figures reflect the established published record. Only some of these have individual citations here. Expert care centers: Only four centers could be verified, all in the U.S. The National Institute on Aging's own center list could not be opened, and no verified center outside the U.S. was found. Financial help: checked October 6, 2026. Most programs are local and pay only for respite care. The Michigan chapter's page gives no amounts or areas, Dementia Care Warriors gives no amounts, and Alzheimer's Arkansas and the Patient Advocate Foundation fund were closed that day. CaringKind (New York City) was left out because its assistance form could not be matched to a program page on its own site.